finance
Sanofi Reports Phase 2 Results for Efdoralprin Alfa in Alpha-1 Antitrypsin Deficiency
Sanofi announced that its Phase 2 Elevaate study showed efdoralprin alfa normalized and maintained functional AAT levels in patients with alpha-1 antitrypsin deficiency. All key secondary endpoints were met and the treatment was well tolerated.
May 18, 3:37 PM·1m read1 source
FI
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Sanofi reported results from its Phase 2 Elevaate study of efdoralprin alfa for alpha-1 antitrypsin deficiency. The study found that the treatment normalized and maintained functional AAT levels. All key secondary endpoints were met.
The safety profile was comparable to plasma-derived protein.
Three-weekly dosing achieved mean functional AAT trough levels three times greater than weekly plasma-derived protein. The treatment was well tolerated in the study.
Transparency
How sources framed this
FI
FI
Single source — no framing comparison available.
CorroborationModerate · 1 source
